ID

34161

Description

Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232); ODM derived from: https://clinicaltrials.gov/show/NCT01881932

Link

https://clinicaltrials.gov/show/NCT01881932

Keywords

  1. 1/14/19 1/14/19 -
Copyright Holder

see on clinicaltrials.gov

Uploaded on

January 14, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Breast Cancer NCT01881932

Eligibility Breast Cancer NCT01881932

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically proven stage i-iii carcinoma of the breast or histologically proven stage i-iii colorectal carcinoma.
Description

ID.1

Data type

boolean

receiving adjuvant or neoadjuvant chemotherapy that includes a taxane or oxaliplatin.
Description

ID.2

Data type

boolean

while on chemotherapy, develop greater than or equal to nci-ctc grade 2 cipn.
Description

ID.3

Data type

boolean

eastern cooperative oncology group performance status 0-2.
Description

ID.4

Data type

boolean

the patient is aware of the nature of his/her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form.
Description

ID.5

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior acupuncture within one year of enrollment.
Description

ID.6

Data type

boolean

known metastatic (stage iv) breast or colorectal cancer involvement.
Description

ID.7

Data type

boolean

pre-existing peripheral neuropathy before chemotherapy is initiated
Description

ID.8

Data type

boolean

currently taking anti-neuropathy medication such as gabapentin, or pregabalin.
Description

ID.9

Data type

boolean

Similar models

Eligibility Breast Cancer NCT01881932

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
histologically proven stage i-iii carcinoma of the breast or histologically proven stage i-iii colorectal carcinoma.
boolean
ID.2
Item
receiving adjuvant or neoadjuvant chemotherapy that includes a taxane or oxaliplatin.
boolean
ID.3
Item
while on chemotherapy, develop greater than or equal to nci-ctc grade 2 cipn.
boolean
ID.4
Item
eastern cooperative oncology group performance status 0-2.
boolean
ID.5
Item
the patient is aware of the nature of his/her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form.
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
prior acupuncture within one year of enrollment.
boolean
ID.7
Item
known metastatic (stage iv) breast or colorectal cancer involvement.
boolean
ID.8
Item
pre-existing peripheral neuropathy before chemotherapy is initiated
boolean
ID.9
Item
currently taking anti-neuropathy medication such as gabapentin, or pregabalin.
boolean

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial